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AbstrAct
Objective to test whether daily high-dose vitamin 
D improves recovery after unilateral total knee 
replacement.
Methods Data come from a 24-month randomised, 
double-blind clinical trial. adults aged 60 and older 
undergoing unilateral joint replacement due to severe 
knee osteoarthritis were 6–8 weeks after surgery 
randomly assigned to receive daily high-dose (2000 iU) or 
standard-dose (800 iU) vitamin D3. the primary endpoints 
were symptoms (Western Ontario and McMaster 
Universities arthritis index pain and function scores) 
assessed at baseline, 6, 12, 18 and 24 months in 
both knees, and the rate of falls over 24 months. 
the secondary outcomes were sit-to-stand performance, 
gait speed, physical activity and radiographic progression 
in the contralateral knee.
Results We recruited 273 participants, 137 were 
randomised to receive 2000 iU and 136 were randomised 
to receive 800 iU vitamin D per day. 2000 iU vitamin D 
increased  25-hydroxyvitamin D levels to 45.6 ng/ml and 
800 iU vitamin D to 37.1 ng/ml at month 24 (p<0.0001). 
While symptoms improved significantly in the operated 
knee and remained stable in the contralateral knee over 
time, none of the primary or secondary endpoints differed 
by treatment group over time. the rate of falls over 24 
months was 1.05 with 2000 iU and 1.07 with 800 iU 
(p=0.84). 30.5% of participants in the 2000 iU and 31.3% 
of participants in the 800 iU group had radiographic 
progression in the contralateral knee over 24 months 
(p=0.88).
Conclusions Our findings suggest that a 24-month 
treatment with daily 2000 iU vitamin D did not show 
greater benefits or harm than a daily standard dose of 800 
iU among older adults undergoing unilateral total knee 
replacement.
InTROduCTIOn
Osteoarthritis (OA) is the leading cause of 
disability in later age,1 and approximately 
30% of individuals aged 65 and older today 
have symptomatic OA marked by pain in the 
affected joint.2 3 Despite its frequency, OA is 
a condition that is poorly understood, with 
no specific treatments to prevent or reverse 
the condition.4 5 Therefore current interven-
tions in patients with OA are limited to symp-
tomatic pain relief. This is initially achieved 
by the use of pain medication, and later with 
total joint replacement.5–7 However, joint 
replacement does not fully restore function 
in most individuals.8 9 Further, adults aged 
65 and older have a more than 50% chance 
of the disease on the contralateral joint,10–12 
which often progresses rapidly10 and likely 
impacts negatively on recovery after total 
joint replacement.
One promising secondary prevention 
strategy in older individuals with symptom-
atic knee OA may be oral vitamin D supple-
mentation. Epidemiological studies suggest 
that increased vitamin D intake and higher 
25-hydroxyvitamin D (25(OH)D) levels may 
be a strategy to prevent structural progression 
of knee OA.13 14 The potential benefit has 
been attributed to a direct effect of vitamin 
D on cartilage cells based on preliminary 
studies and in vitro findings.15–17 However, all 
three recent clinical trials that assessed radio-
graphic progression among patients with 
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Key messages
What is already known about this subject?
 ► epidemiological studies suggest that increased vitamin D intake 
and higher 25-hydroxyvitamin D levels may prevent structural pro-
gression of knee  osteoarthritis (Oa).
 ► However, all four recent clinical trials testing vitamin D supplemen-
tation found no such benefit among patients with early to moderate 
Oa not yet at the stage of surgery.
What does this study add?
 ► in this trial, we focus on older adults aged 60 years and older under-
going unilateral total knee replacement due to severe knee Oa and 
include the risk of falling as a primary endpoint.
 ► Further, we compare a standard of care dose of vitamin D (800 iU 
per day) with a high dose (2000 iU vitamin D) to explore if a higher 
dose is more effective.
 ► For Oa outcomes, we assess pain and function both for the operat-
ed and the contralateral knee.
 ► While participants showed significant improvements in symptoms 
in the operated knee and no worsening of symptoms in the contra-
lateral knee, a daily higher dose of 2000 iU did not show greater 
benefits than a daily standard dose of 800 iU; this included a similar 
rate of falling between treatment groups and a similar per cent of 
participants with radiographic progression in the contralateral knee 
over 24 months.
How might this impact on clinical practice?
 ► Our findings suggest that a daily dose of vitamin D greater than 800 
iU vitamin D is not needed for recovery after unilateral total knee 
replacement due to severe knee Oa.
 ►  the efficacy of an 800 iU dose without a pure control group could 
not be evaluated.
 ► Our findings also suggest that the higher daily dose of 2000 iU com-
pared with 800 iU vitamin D per day is safe among older  adults 
undergoing unilateral knee replacement due to Oa.
symptomatic knee OA found no benefit on MRI-based 
tibial cartilage volume18 19 or X-ray-based joint space 
narrowing20 with vitamin D supplementation compared 
with placebo.
Alternatively, vitamin D may have a beneficial effect 
on muscle surrounding the OA-affected joint.21 This is 
supported by the presence of the vitamin D receptor,22–24 
as well as an evidence from several clinical trials suggesting 
that daily 800 IU vitamin D supplementation among 
adults aged 65+ at risk of vitamin D deficiency improves 
lower extremity function25 and reduces the risk of falls26 
and related fractures.27 28 Given that vitamin D deficiency 
is common among individuals with knee OA29 and symp-
tomatic knee OA has been shown to double the risk of 
falls and hip fractures,30 vitamin D supplementation may 
have clinical relevance in these patients. Notably, one 
smaller clinical trial of 107 patients suggested a signifi-
cant improvement in both pain and function among 
middle-aged adults treated with vitamin D compared with 
placebo.31
To our knowledge, no clinical trial has been performed 
to test the benefit of vitamin D on fall prevention or 
recovery after unilateral knee replacement among 
patients with severe knee OA. Therefore, our primary 
goals were to examine whether 2000 IU vitamin D 
improved symptoms (pain and function) in the operated 
knee, reduced falls and slowed the progression of symp-
toms in the contralateral knee, relative to a standard dose 
of 800 IU vitamin D. Notably, the study did not include 
a placebo group as the ethical commission at the time 
requested that the comparator should be standard-dose 
800 IU vitamin D to allow compliance with current recom-
mendations given the high risk of falls and hip fractures 
among seniors with knee OA.30 The high dose of 2000 IU 
vitamin D was chosen because it was previously found to 
be more effective than the standard 800 IU vitamin D in 
shifting most individuals to a target therapeutic range of 
24–30 ng/mL,32 where a maximum benefit with regard to 
knee OA disease progression33 as well as fall and fracture 
prevention was expected.28 34
MeTHOds
Trial design
This is a single-centre, double-blind randomised trial. 
All participants gave written informed consent for partic-
ipation in the trial. The trial was registered at  Clinical-
Trials. gov: https:// clinicaltrials. gov/ ct2/ show/ results/ 
NCT00599807. Clinical visits were performed by all 
participants at baseline (6–8 weeks after unilateral total 
knee replacement surgery), and at months 6, 12, 18 and 
24 after baseline. Between clinical visits, the study nurses 
called the participants every 2 months to assess falls, 
adverse events and adherence to study medication.
setting and locations
The study was performed at the Center on Aging and 
Mobility at the University Hospital Zurich, with the first 
patient enrolled in the study in January 2008 and the last 
patient follow-up visit in March 2014.
Participants and screening procedures
Participants were recruited from two large hospital 
centres (Schulthess Clinic Zurich, Triemli City Hospital) 
with a multistep screening process (see also figure 1). 
Those who were eligible based on the prescreening ques-
tionnaire and gave their preconsent to participate in the 
trial filled out the Western Ontario and McMaster Univer-
sities Arthritis Index (WOMAC; score 0–100) prior to 
their surgery. This instrument was used to capture presur-
gery symptoms, and later to stratify randomisation. Those 
who met all the inclusion and exclusion criteria and gave 
written informed consent (n=273) were enrolled in the 
trial at 6–8 weeks after surgery.
Inclusion and exclusion criteria
Eligible patients were aged 60 years and older, underwent 
unilateral total knee replacement due to severe knee OA 
and did not plan bilateral knee replacement within the 
next 2 years. Further eligibility criteria included willing-
ness to stop current vitamin D and calcium supplements 
during the trial, fluent oral and written language skills in 
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Figure 1  Study recruitment and follow-up.
German, and a score of at least 24 (of 30) points in the 
Mini-Mental State Examination cognitive test. Key exclu-
sion criteria were history of inflammatory arthritis and 
inability to walk at least 3 m with or without a walking aid 
(for additional exclusion criteria, see online supplemen-
tary appendix 1).
Interventions
Participants were randomised to either one capsule 
containing 2000 IU vitamin D3/day or one capsule 
containing 800 IU vitamin D3/day. Vitamin D capsules 
were produced by the cantonal pharmacy of Zurich 
and had identical appearances and taste, and assays 
confirmed the expected contents (eight assessments of 
individual batches varied between 2017 and 2115 IU for 
the high-dose group, and between 797 and 864 IU for 
the standard-dose group). All participants received a 500 
mg supplement of calcium per day (calcium carbonate; 
Sandoz Switzerland).
Outcomes
Primary outcomes
WOMAC symptoms were assessed for the operated and 
the contralateral knee (function and pain subscales range 
from 0 to 100, with 0 indicating optimal function and no 
pain).35 The rate of falls was assessed over 24 months 
by diary and by phone calls every 2 months. Falls were 
defined as ‘unintentionally coming to rest on the ground, 
floor, or other lower level’; coming to rest against furni-
ture or a wall was not counted.36 The primary endpoints, 
WOMAC pain and function scores, were assessed at base-
line, 6, 12, 18 and 24 months in both knees, and the rate 
of falls over 24 months.
Secondary outcomes
Repeated sit-to-stand test performance and 4 m normal 
gait speed were assessed at all clinical visits. Physical 
activity was measured at baseline, 12 and 24 months by 
a seven consecutive day ankle-worn ambulatory activity 
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monitor (StepWatch Step Activity Monitor, Cyma, 
Seattle, Washington)37 38 (see online supplementary 
appendix 1 for additional details on the physical activity 
assessment and analysis). Radiographic progression in 
the contralateral knee was assessed at baseline and at 
24-month follow-up (see section above) and is detailed in 
online supplementary appendix 1. In short, we used the 
Multicentre Osteoarthritis Study (MOST) study centre 
standardised X-ray assessment procedures,39 and X-rays 
were evaluated by two blinded expert readers using two 
published approaches detecting changes in radiographs 
due to OA.40 41
Randomisation–blinding–treatment allocation
Randomisation lists were computer-generated by the trial 
statistician (EJO), with separate lists stratified by presur-
gery WOMAC function score (<52 vs ≥5235 in the oper-
ated knee, presence of OA in the non-operated knee and 
recruitment centre). Each list was blocked in groups of 
4 to assure balance. The randomisation lists were sent 
directly and exclusively to the cantonal pharmacy in 
Zurich, Switzerland, which carried out the blinding and 
labelling of the study medication. This pharmacy was 
located outside the study centre with no access for study 
team members. The participants and all trial staff were 
blinded to treatment allocation.
Vitamin d and other laboratory assessments
Fasting blood and urine (second voiding) samples 
were taken between 08:00 and 09:30 at all clinical visits. 
The 25(OH)D serum concentrations were measured by a 
sensitive high-performance liquid chromatography mass 
spectrometry with multiple steps of mass spectrometry 
selection (HPLC-MS/MS) method42 43 included in the 
National Institute of Standards and Technology/National 
Institutes of Health Vitamin D Metabolites Quality Assur-
ance Program44 at baseline, 6 months and 24 months. 
Intact parathyroid hormone (iPTH), serum calcium and 
creatinine, and urinary calcium to creatinine ratio were 
measured at baseline and at months 6, 12, 18 and 24 
using the cobas 8000 system and assays from Roche Diag-
nostics (Rotkreuz, Switzerland) c501 machine.
sample size analysis
Our study was designed to enrol 287 patients in order 
to detect a 38% relative difference in the rate of falls 
between the two intervention groups. For the rate of 
falls, our power calculation is based on a conservative 
estimate from a European trial data on ambulatory older 
women, which suggested a 46% difference in the rate of 
falls between the vitamin D group and the control group 
over a 12-month follow-up.45 We reduced the expected 
rate difference to 38% as our trial included men and 
women.46 Assuming full 24-month follow-up on 220 of 
the patients and at least 12-month follow-up on 234 of the 
patients, we would have had a power of 80% (two-sided 
alpha=0.05). During the trial, we recruited slightly fewer 
patients (273), but more of them (226) completed the 
full 24-month protocol, providing adequate power for 
our analyses.
statistical analyses
A longitudinal linear regression with random intercepts 
for each patient was used to account for correlation over 
time (baseline, 6, 12, 18 and 24 months) for continuous 
variables. The primary predictors in each model were 
categorical time, intervention group, and the interaction 
between intervention and time. These models were run 
initially with no adjustment covariates. The models for 
primary and secondary outcomes adjusted for design 
stratification covariates (preoperative WOMAC function 
score (<52 vs ≥52) in the operated knee, presence of 
OA in the contralateral knee and recruitment centre) as 
well as four prechosen covariates considered to be clini-
cally important (baseline age, gender, body mass index 
(BMI) and Charlson Comorbidity Index). Since five 
primary outcomes were specified in our protocol (pain 
and function over time in the operated and contralateral 
knee and rate of falls), a Bonferroni-adjusted p value 
of <0.01 should be considered evidence of significance. 
For the rate of falls, we used a simple Poisson regression 
model, including the number of months of follow-up as 
an offset. For the percentages of patients with any falls, we 
used a logistic regression model and included a patient’s 
follow-up time as a covariate in all models.
Each of the analyses was an intention-to-treat analysis. 
Predefined subgroup analyses included gender, preoper-
ative WOMAC function score (<52 vs ≥5235 in the oper-
ated knee and presence of OA in the contralateral knee). 
We first added a three-way interaction term between each 
of these characteristics, time and intervention group 
to the model. If that term was significant at p<0.10, we 
examined the intervention effect within each subgroup.
ResulTs
Participants
Figure 1 shows the conduct of the trial. Because of slow 
accrual, the study closed before the last 27 subjects 
reached their 24-month follow-up visits. These partici-
pants were included in all analyses. Notably, of the actual 
20 dropouts, 4 were deaths, and thus the true dropout 
rate was 5.8% (16 of 273). At baseline, all variables but 
weight and BMI were balanced between the treatment 
groups (table 1).
Adherence to study medication and changes in 25(OH)d 
and iPTH serum concentrations by treatment groups and 
biochemical safety
Based on 2-monthly phone-based assessments, 93% of 
participants in the 800 IU group and 92% in the 2000 IU 
group were at least 80% adherent to the vitamin D study 
medication. Changes in 25(OH)D serum concentrations 
are shown in table 2. After adjustment for all covariates, 
800 IU vitamin D per day increased 25(OH)D to 40.4 ng/
mL at 6 months and to 37.1 ng/mL at 24 months. With 
2000 IU vitamin D, 25(OH)D levels increased to 47.0 ng/
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Table 1  Baseline characteristics by treatment
Total 
participants 800 IU vitamin D3 2000 IU vitamin D3
Difference
(p values)
Participants, n (%) 273 (100) 136 (49.8) 137 (50.2)
Women, n (%) 146 (53.5) 77 (56.6) 69 (50.4) 0.30
Age (years) 70.3 (6.4) 70.5 (6.0) 70.2 (6.8) 0.67
Patients ≥70 years, n (%) 130 (47.6) 70 (51.5) 60 (43.8) 0.20
Low preoperative WOMAC function score, n (%)* 50 (18.3) 25 (18.4) 25 (18.3) 0.98
Osteoarthritis also on the other knee, n (%) 223 (81.7) 112 (82.4) 111 (81.0) 0.78
Height (cm) 168.4 (9.2) 167.7 (9.1) 169.2 (9.3) 0.17
Weight (kg) 77.5 (14) 75.4 (14.3) 79.5 (13.4) 0.02
Body mass index (kg/m2) 27.2 (3.9) 26.7 (4.1) 27.7 (3.8) 0.04
Charlson Comorbidity Index (score 0–37) 0.5 (0.9) 0.5 (1) 0.5 (0.8) 0.82
Mini-Mental State Examination (score 0–30) 28.0 (1.5) 28.1 (1.2) 27.8 (1.6) 0.21
Baseline 25-hydroxyvitamin D (ng/mL) 27.3 (12.4) 27.2 (12.7) 27.3 (12.2) 0.96
  <10, n (%) 17 (6.3) 8 (6.0) 9 (6.6) 0.84
  <20, n (%) 85 (31.4) 44 (32.8) 41 (29.9) 0.61
WOMAC scores (score 0–100)
  Pain operated knee 28.5 (15.0) 28.3 (15.9) 28.7 (14.1) 0.81
  Pain non-operated knee 4.7 (8.1) 4.7 (7.6) 4.7 (8.7) 0.96
  Function operated knee 25.8 (13.8) 25.3 (14.3) 26.2 (13.3) 0.58
  Function non-operated knee 4.2 (8.0) 4.2 (7.9) 4.3 (8.1) 0.98
Functional performance tests
  Repeated sit-to-stand test (score 0–4) 3.4 (1.0) 3.4 (0.9) 3.4 (1.0) 0.88
  Gait speed, 4 m (s) 4.4 (0.9) 4.3 (1.0) 4.4 (0.8) 0.33
Physical activity (min MVPA/day) 42.1 (22.5) 42.2 (22.0) 41.9 (23.2) 0.92
Kellgren-Lawrence grades, n (%), contralateral 
knee
  0 57 (21.1) 29 (21.3) 28 (20.9) 0.66
  1 62 (23.0) 33 (24.3) 29 (21.6)
  2 54 (20.0) 25 (18.4) 29 (21.6)
  3 73 (27.0) 34 (25.0) 39 (29.1)
  4 24 (8.9) 15 (11.0) 9 (6.8)
Data (n=273) are crude mean (±SD) or n (%). Differences between treatment groups (800 vs 2000 IU vitamin D3) were assessed using 
Student’s t-test and Wilcoxon test for continuous variables and χ2 test for categorical variables. P values are two-sided; statistical 
significance was set at p<0.05.
*Preoperative WOMAC function score in the operated knee <52.
MVPA, medium-to-vigorous physical activity; WOMAC, Western Ontario and McMaster Universities Arthritis Index.
mL at 6 months and 45.5 ng/mL at 24 months. Adjusted 
levels for iPTH did not differ by treatment, although 
there was a significant increase over time in the 800 IU 
group (table 2).
Primary endpoints: symptoms (pain and function) and falls
Both treatment groups experienced a significant func-
tional improvement and pain reduction from baseline 
(6–8 weeks after unilateral knee replacement) across 
time in the operated knee (p<0.0001), while symptoms 
remained unchanged over time in the contralateral knee 
(see table 3A and figure 2). In both knees, symptoms did 
not differ by treatment at any time point, nor over the 
whole follow-up across 24 months.
Over 24 months 158 of 273 participants sustained 307 
falls, of which 157 occurred in the 800 IU group and 150 
in the 2000 IU group. Fourteen participants had more 
than four falls (nine with standard-dose and five with 
high-dose), which according to protocol were truncated 
to four for the analyses in table 3A. The adjusted mean 
number of falls was similar in both treatment groups over 
the 24 months of follow-up (1.07 falls in the standard vs 
1.05 in the high-dose vitamin D group, p=0.84). A similar 
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Table 2  Change in serum 25(OHD) and iPTH concentration at 6-month and 24-month follow-up by treatment
Standard-dose
800 IU vitamin D3
(n=136)
High-dose
2000 IU vitamin D3
(n=137)
P value* difference 
by time point
P value† difference 
over time
25(OH)D (ng/mL)
  Baseline 26.8 (24.9 to 28.7) 27.7 (25.8 to 29.6) 0.51 <0.0001
  6 months 40.4 (38.4 to 42.3) 47.0 (45.1 to 49.0) <0.0001
  24 months 37.1 (35.1 to 39.2) 45.5 (43.5 to 47.6) <0.0001
  Pover time‡ <0.0001 <0.0001
iPTH (ng/L)
  Baseline 49.8 (46.8 to 52.9) 48.7 (45.7 to 51.7) 0.62 0.22
  6 months 50.5 (47.4 to 53.5) 47.8 (44.8 to 50.9) 0.22
  12 months 52.7 (49.6 to 55.8) 48.5 (45.4 to 51.6) 0.06
  18 months 53.5 (50.4 to 56.6) 49.5 (46.4 to 52.6) 0.07
  24 months 52.4 (49.3 to 55.6) 48.8 (45.7 to 52.0) 0.11
  Pover time‡ 0.004 0.59
Data show LSM (95% CI) of repeated measurements of serum 25-OH(D) and iPTH concentration by treatment group from multivariable 
repeated-measures models. Models included an indicator variable for treatment, visit, and the interaction between treatment and visit, and 
were adjusted for preoperative Western Ontario and McMaster Universities Arthritis Index.
Function score (<52 vs ≥52 in the operated knee), presence of osteoarthritis in the non-operated knee, hospital site, and baseline age, 
gender, body mass index and Charlson Comorbidity Index (score 0–37). P values are two-sided. Statistical significance was set at p<0.05.
*P value for the difference in 25(OH)D and iPTH concentration by treatment group at baseline and individual follow-up time points.
†P value for the overall treatment effect across the repeated measurements of 25(OH)D and iPTH concentration.
‡P value for the change in 25(OH)D and iPTH concentration within treatment groups over time.
25(OH)D, 25-hydroxyvitamin D; iPTH; intact parathyroid hormone; LSM, least-square means.
pattern was seen over the first 12 months of follow-up 
(see table 3A). Although not a primary endpoint, we also 
compared the percentage of patient who fell and found 
no difference between the arms (see table 3A).
secondary endpoints: lower extremity function, physical 
activity and radiographic progression in the contralateral 
knee
Both treatment groups experienced a significant gain 
in lower extremity function from baseline (6–8 weeks 
after unilateral knee replacement) to 6, 12, 18 and 24 
months of follow-up (p<0.0001; see table 3B). For both 
lower extremity function test sit-to-stand (STS) and 
gait speed, the difference between treatment groups 
approached significance (p=0.09 for each), with a 
possibly more pronounced improvement in the 2000 IU 
group. StepWatch-based physical activity also increased 
significantly over time, but not differentially so by treat-
ment group (p=0.84; see table 3B).
Based on standardised X-rays of the contralateral knee, 
31.3% of participants in the standard-dose and 30.5% 
of participants in the high-dose group progressed from 
baseline to 24 months, but again with no difference 
between the treatment groups (p=0.88; see table 3B).
subgroup analyses
As predefined in the study protocol, we tested three 
interactions with treatment for the primary endpoints: by 
gender, by WOMAC function in the operated knee prior 
to surgery (<52 vs ≥52) and by OA in the contralateral 
knee at baseline (see online supplementary appendix 2). 
One interaction with treatment was found for gender, 
suggesting that high-dose vitamin D may improve 
WOMAC pain in the operated knee among men but 
not among women. The other interaction was found for 
treatment and function prior to surgery, where seniors 
with a lower function may have an increased chance to 
fall with high-dose vitamin D.
Biochemical safety
Regarding biochemical safety (see online supplemen-
tary appendix 3), mean serum calcium, and creatinine 
levels and mean urinary calcium excretion did not differ 
by treatment group at baseline and at 6, 12, 18 and 24 
months of follow-up. There were few cases (between 0 
and 4) of mild hypercalcaemia (>2.6 mmol/L) balanced 
between the treatment groups at all time points. At none 
of the time points were there any cases of overt hyper-
calcaemia >3.0 mmol/L (see online supplementary 
appendix 3).
dIsCussIOn
Our study shows that among patients aged 60 and above, 
a higher dose of 2000 IU daily vitamin D supplementation 
compared with a standard dose of 800 IU daily vitamin 
D supplementation does not improve outcomes after 
total unilateral knee replacement. This includes pain 
and function in the operated and contralateral knees, as 
well as the rate of falls. While this strongly suggests that a 
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Table 3 (A) Primary and secondary endpoints — by treatment
(A) Primary endpoints 
Standard-dose
800 IU vitamin D3
n=136
High-dose
2000 IU vitamin D3
n=137 P values*
P value difference over time†
WOMAC function, operated knee P=0.94
Baseline 25.0 (23.3, 26.8) 26.3 (24.6, 28.1) 0.31
6 months 9.9 (8.1, 11.6) 10.8 (9.0, 12.5) 0.49
12 months 7.9 (6.1, 9.6) 8.2 (6.4, 9.9) 0.82
18 months 7.2 (5.4, 9.0) 8.0 (6.2, 9.8) 0.56
24 months 6.6 (4.8, 8.5) 7.0 (5.2, 8.9) 0.77
Pacross time‡ <0.0001 <0.0001
WOMAC pain, operated knee P=0.97
Baseline 28.0 (26.1, 29.9) 28.9 (27.0, 30.7) 0.54
6 months 9.1 (7.2, 11.0) 10.0 (8.0, 11.9) 0.52
12 months 6.2 (4.3, 8.1) 6.8 (4.9, 8.7) 0.66
18 months 5.7 (3.8, 7.7) 6.3 (4.3, 8.3) 0.70
24 months 6.4 (4.4, 8.4) 6.2 (4.2, 8.2) 0.92
Pacross time‡ <0.0001 <0.0001
WOMAC function, contralateral knee P=0.36
Baseline 4.2 (2.8, 5.6) 4.3 (2.9, 5.7) 0.94
6 months 6.1 (4.7, 7.5) 4.6 (3.2, 6.0) 0.15
12 months 5.1 (3.7, 6.6) 4.7 (3.2, 6.1) 0.67
18 months 5.3 (3.9, 6.8) 5.3 (3.8, 6.7) 0.94
24 months 4.1 (2.6, 5.6) 4.6 (3.1, 6.1) 0.68
Pacross time‡ 0.63 0.06
WOMAC pain, contralateral knee P=0.59
Baseline 4.7 (2.9, 6.4) 4.6 (2.9, 6.4) 0.98
6 months 6.9 (5.1, 8.6) 5.2 (3.5, 7.0) 0.20
12 months 6.4 (4.6, 8.2) 5.2 (3.5, 7.0) 0.37
18 months 6.5 (4.7, 8.3) 5.5 (3.7, 7.3) 0.44
24 months 6.5 (3.6, 7.3) 5.8 (3.9, 7.6) 0.84
Pacross time‡ 0.19 0.80
Rate of falls (mean)
Baseline to 12 months 0.53 (0.32, 0.83) 0.45 (0.27, 0.72) 0.27
Baseline to 24 months 1.07 (0.92, 1.23) 1.05 (0.90, 1.21) 0.84
(B) Secondary endpoints 
Secondary endpoints
Least-square means
P values†
Standard-dose
800 IU vitamin D3
High-dose
2000 IU vitamin D3
 P value difference over time*
Sit-to-stand performance in seconds P=0.09
Baseline 10.7 (10.2, 11.2) 11.1 (10.6, 11.6) 0.28
6 months 9.7 (9.2, 10.1) 9.3 (8.8, 9.8) 0.32
12 months 9.2 (8.7, 9.7) 9.2 (8.7, 9.7) 0.90
18 months 9.2 (8.7, 9.7) 9.0 (8.5, 9.5) 0.48
Continued
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(B) Secondary endpoints 
Secondary endpoints
Least-square means
P values†
Standard-dose
800 IU vitamin D3
High-dose
2000 IU vitamin D3
24 months 9.0 (8.5, 9.5) 8.6 (8.1, 9.2) 0.34
Pacross time‡ <0.0001 <0.0001
4 m normal gait in seconds P=0.09
Baseline 4.3 (4.2, 4.4) 4.4 (4.3, 4.5) 0.13
6 months 4.0 (3.9, 4.1) 3.9 (3.8, 4.0) 0.18
12 months 3.8 (3.6, 3.9) 3.7 (3.6, 3.8) 0.47
18 months 3.7 (3.6, 3.9) 3.7 (3.6, 3.9) 0.96
24 months 3.7 (3.5, 3.8) 3.7 (3.6, 3.8) 0.44
Pacross time‡ <0.0001 <0.0001
StepWatch physical activity P=0.84
Baseline 41.6 (37.5, 45.7) 42.0 (37.9, 46.1) 0.89
12 months 51.6 (47.4, 55.9) 50.3 (46.1, 54.6) 0.68
24 months 49.1 (44.8, 53.4) 48.6 (44.3, 52.9) 0.48
Pacross time‡ <0.0001 <0.0001
Percentage of participants with radiographic progression of 
the non-operated knee
Baseline to 24 months 31.3 (23.5, 40.4) 30.5 (22.6, 39.6) 0.88
In both treatment groups, we found significant within-group improvements for symptoms (WOMAC function and pain) in the operated knee, 
lower extremity function (sit-to-stand performance, 4 m normal gait) and physical activity. Also, in both treatment groups, we found no 
progression of symptoms (WOMAC function and pain) and an about 30% radiographic progression in the contralateral knee. For WOMAC 
symptoms, the number of patients followed in the 800 IU group at each time point was baseline=136, 6 months=130, 12 months=130, 
18 months=123 and 24 months=115. The number of patients followed in the 2000 IU group at each time point was baseline=137, 
6 months=129, 12 months=125, 18 months=118 and 24 months=111. For falls, all 273 participants are included in all analyses. All 
models included an indicator variable for treatment, time, and the interaction between treatment and time, and were adjusted for the 
preoperative WOMAC function score (<52 vs ≥52) in the operated knee, presence of osteoarthritis in the non-operated knee, hospital 
site, and baseline age, gender, body mass index and Charlson Comorbidity Index (score 0–37). Repeated-measures linear regression for 
WOMAC function and pain. Binomial regression model for the rate of falls—with same adjustments but without indicator variable time and 
without interaction assignment*time. Adjusting for five primary outcome variables, a Bonferroni-adjusted p value of 0.01 is required for 
statistical significance. 
P values are two-sided. Statistical significance was set at p<0.05.
*P value for the treatment effect at each time point.
†P value for the overall treatment effect across the repeated measurements for WOMAC pain and function, sit-to-stand performance, 4 m 
normal gait in seconds and StepWatch physical activity.
‡P value for the change within treatment groups from 0 to 24 months.
WOMAC, Western Ontario and McMaster Universities Arthritis Index.
Table 3  Continued
higher dose of 2000 IU is not necessary for recovery after 
unilateral total knee replacement, we cannot determine 
the degree of efficacy of the 800 IU dose without a pure 
control group.
The only significant dose-differential findings were 
identified in predefined subgroup analyses by gender and 
by function prior to surgery. Based on these, we cannot 
exclude the possibility that men may benefit from 2000 
IU superior to 800 IU vitamin D with respect to a signifi-
cantly greater pain reduction in their operated knee. On 
the other hand, we also cannot exclude the possibility 
that 2000 IU vitamin D may increase fall risk significantly 
among patients who are most limited in their WOMAC 
function at the index knee prior to surgery.
Our trial is the fifth in a recent series of double-blind 
randomised controlled trials18–20 31 on vitamin D supple-
mentation among patients with symptomatic knee OA. 
Compared with the prior trials, we targeted somewhat 
older adults with a mean age of 70 years versus aged 
53–64 and not yet at the stage of surgery in the previous 
four trials. Unique to our trial is also the concept of 
targeting WOMAC symptoms individually for the oper-
ated and the contralateral knee, to investigate both 
recovery of the operated knee as well as progression in 
the contralateral non-operated knee.47 For the latter, 
we anticipated10–12 and confirmed a high 57% preva-
lence of radiographic OA in the contralateral knee at 
baseline. However, contrary to our expectations, we did 
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Figure 2  WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and 
contralateral knee over time and by treatment. The number of patients followed in the 800 IU group at each time point was 
baseline (BL)=136, 6 months=130, 12 months=130,18 months=123 and 24 months=115. The number of patients followed in 
the 2000 IU group at each time point was baseline=137, 6 months=129, 12 months=125, 18 months=118 and 24 months=111. 
Data points show least-square means based on repeated measurement analyses that included an indicator variable for 
treatment (800 IU vitamin D vs 2000 IU vitamin D), time, and the interaction between treatment and time, and were adjusted 
for the preoperative WOMAC function score (<52 vs ≥52) in the operated knee, presence of osteoarthritis in the non-operated 
knee, hospital site, and baseline age, gender, body mass index and Charlson Comorbidity Index (score 0–37). Symptoms in the 
operated knee (black) improved significantly over time for both function and pain, but not differentially by treatment. Symptoms 
in the contralateral knee (grey) stayed constant over time and did not change between treatment groups.
not find rapid disease progression10 in the contralateral 
knee, both clinically and radiographically. In fact, for 
symptoms, the majority of participants in both treatment 
groups remained stable.
One explanation may be that 800 IU vitamin D may have 
been sufficient to stop symptomatic progression in the 
contralateral knee. Supporting such a benefit, in three18 19 31 
of the four prior trials, a benefit of vitamin D on WOMAC 
function could not be excluded, and one31 of the four prior 
trials found a significant improvement in WOMAC pain. 
However, regarding structural disease progression, none of 
the prior trials support such a benefit.
We confirm the high risk of falling in this patient 
group.48 However, the adjusted mean number of falls over 
24 months was similar between the treatment groups. 
Only in the subgroup with most pronounced functional 
limitations prior to surgery more falls occurred with 
2000 IU vitamin D compared with 800 IU vitamin D. 
This is consistent with one prior trial among 173 patients 
with hip fracture, where a possible increase of falls with 
2000 IU vitamin D/day vs 800 IU/day could not be 
excluded (+28%; 95% CI −4% to +68%).34
A limitation of our study is the lack of a pure control 
group, which is why our trial cannot establish a benefit 
of daily 800 IU vitamin D over placebo. However, at the 
time of the trial (start in 2007), the safe upper intake 
of vitamin D was still 2000 IU, and the ethical commis-
sion at the time requested that the comparator should 
be the standard-dose 800 IU vitamin D to allow compli-
ance with current recommendations given the high 
risk of falls and hip fractures among seniors with knee 
OA.30 Also, contrary to our expectations,49 only 31.4% of 
participants were vitamin D-deficient at baseline, and the 
achieved 25(OH)D levels only differed by 6.6 ng/mL at 6 
months and 8.4 ng/mL at 24 months.34
In conclusion, our findings suggest that daily 800 IU 
vitamin D may be sufficient for recovery after unilateral 
total knee replacement due to severe knee OA. However, 
despite the observed improvement in symptoms among 
participants of both treatment groups in our trial, we 
cannot determine the degree of efficacy of the 800 IU 
dose without a pure control group. More research is 
needed to clarify the potential benefit of vitamin D on 
OA symptoms.
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